Cadrenal Therapeutics Inc.

11/16/2026 | Press release | Distributed by Public on 11/16/2026 16:18

Quarterly Report for Quarter Ending September 30, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following management's discussion and analysis of our financial condition and results of operations in conjunction with our unaudited financial statements and notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q and with our audited financial statements and notes thereto for the year ended December 31, 2025, included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed on March 31, 2026 ((the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC"). This discussion, particularly information with respect to our future results of operations or financial condition, business strategy, plans and objectives for future operations, includes forward-looking statements that involve risks and uncertainties as described under the heading "Special note regarding forward-looking statements" in this Quarterly Report on Form 10-Q. You should review the disclosure under Part I, Item 1A of the Annual Report for a discussion of important factors that could cause our actual results to differ materially from those anticipated in these forward-looking statements. References in this Quarterly Report on Form 10-Q to "we," "us," "our" and similar first-person expressions refer to Cadrenal Therapeutics, Inc. ("Cadrenal").

Special Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed in the forward-looking statements. The statements contained in this report that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the use of words such as, but not limited to, "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "plan," "project," "seek," "should," "strategy," "target," "will," "would" and similar expressions or variations intended to identify forward-looking statements. These statements are based on the beliefs and assumptions of our management based on information currently available to management. Such forward-looking statements are subject to risks, uncertainties and other important factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified under Part 1, Item 1A of the Annual Report. Furthermore, such forward-looking statements speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements to reflect events or circumstances after the date of such statements.

Company Overview

We are a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Our development pipeline is anchored by four assets targeting acute medical needs:

● CAD-1005: A first-in-class 12-lipoxygenase (12-LOX) inhibitor being developed for Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI).
● Tecarfarin: A late-stage Vitamin K antagonist (VKA) designed to prevent systemic thromboembolism.
● Frunexian: An intravenous Factor XIa inhibitor.
● CAD-2000: Our next-generation oral 12-LOX platform.

FDA Alignment on Phase 3 Registrational Trial for CAD-1005

On August 31, 2026, we announced positive feedback from a Type D meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026.. During the meeting, we and the FDA aligned on key aspects of the protocol and Statistical Analysis Plan (SAP) for our Phase 3 registrational study of CAD-1005 in patients with HIT.

Key clinical consensus items included:

● Primary Endpoint Protocol: Agreement on an optimized definition of worsening HIT for the primary endpoint, measured through Day 14 or hospital discharge. The endpoint will assess the proportion of Serotonin Release Assay-positive (SRA+) participants with adjudicated new or worsening composite thromboembolic events.
● Reduced Site Variability: The worsening component incorporates strict metrics assessing the extension of an existing thrombus into a new vascular segment or bed, avoiding potential site to site variability from manual size measurement.
● Trial Architecture: The FDA agreed to use placebo control in the Phase 3 trial, with existing standard anticoagulation therapeutics for both the CAD-1005 and placebo control arms.

CAD-1005 continues to hold valuable FDA Orphan Drug and Fast Track designations, along with orphan drug status from the European Medicines Agency (EMA).

Engagement of Strategic Financial Advisor

On October 7, 2026, building on our pipeline's regulatory maturity and ongoing inbound interest, our Board of Directors initiated a formal strategic review to maximize our value and the value of our asset portfolio. In connection with this initiative, we retained Tungsten Advisors as our exclusive strategic financial advisor to lead the review.

The strategic review will evaluate multiple structural alternatives to maximize portfolio value, including:

● Asset Monetization: Out-licensing, regional co-development rights, or the outright sale of individual pipeline assets like CAD-1005 or tecarfarin.
● Strategic Alliances: Deep operational and commercialization partnerships with global pharmaceutical entities.
● Corporate Transactions: Corporate mergers, portfolio combinations, or other comprehensive business combinations.

There is no assurance that this strategic review process will result in any definitive transaction. We do not intend to disclose further developments regarding this process unless or until our Board of Directors has approved a specific transaction or formally concluded the review, or the Company otherwise determines that disclosure id appropriate or required.

Strategic Status of Alternative Assets

While our strategic evaluation process centers on the clinical positioning of CAD-1005, the Board of Directors and Tungsten Advisors are concurrently evaluating strategic paths to maximize the inherent value of our alternative pipeline assets, tecarfarin and frunexian:

● Tecarfarin: Our late-stage Vitamin K antagonist (VKA) is being designed to avoid the metabolic pathways that cause unpredictable dosing and side effects seen with traditional anticoagulants. Given its advanced development stage and historical data, the strategic review is focusing on out-licensing opportunities in specific geographic territories or for specialized patient populations-such as patients with end-stage renal disease (ESRD) and atrial fibrillation or those requiring mechanical heart valve, including implemented left ventricular assist devices (LVADs)-where direct oral anticoagulants (DOACs) are currently contraindicated.
● Tecarfarin Regulatory Developments (RPDD Amendment): On October 22, 2026, we systematically responded to an FDA Office of Orphan Products Development deficiency letter regarding our Rare Pediatric Disease Designation (RPDD) request (# RPD-2026-1250). To align with the Agency's guidance, we formally restricted our proposed pediatric indication to a severe, anatomically verifiable sub-population: the prevention of acute myocardial infarction and luminal occlusion in pediatric patients with Chronic Kawasaki Disease-Induced Giant Coronary Artery Aneurysms. Longitudinal epidemiological models submitted to the FDA project that this limits the newly eligible annual target prevention pool to approximately 28 to 55 patients across the United States, well below the statutory ceilings required for rare disease classification.
● Frunexian: Our intravenous Factor XIa inhibitor is being developed for acute and critical care settings, including major cardiac surgery. Strategic alternatives under consideration include co-development alliances and joint ventures with global pharmaceutical partners to fund and accelerate its clinical development, thereby mitigating our independent research and development financial exposure.

Recent Financing Developments

PIPE Transaction

On June 30, 2026, we entered into a securities purchase agreement with an investor, pursuant to which we issued and sold, in a private placement priced at-the-market under the rules of the Nasdaq Stock Market (the "PIPE Transaction"), (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 960,000 shares (the "Pre-Funded Warrant Shares") of our common stock, par value $0.001 per share (the "Common Stock"), (ii) Series C-1 Common Stock warrants (the "Series C-1 Warrants") to purchase up to an aggregate of 960,000 shares (the "Series C-1 Warrant Shares") of Common Stock, and (iii) Series C-2 Common Stock warrants (the "Series C-2 Warrants" and, together with the Series C-1 Warrants, the "Common Warrants") to purchase up to an aggregate of 960,000 shares (the "Series C-2 Warrant Shares" and, together with the Pre-Funded Warrant Shares and the Series C-1 Warrant Shares, the "PIPE Warrant Shares") of Common Stock, at a combined purchase price of $3.1249 per Pre-Funded Warrant and accompanying Common Warrants. We received aggregate gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses.

The Pre-Funded Warrants have an exercise price of $0.0001 per share, are exercisable immediately, and do not expire until exercised in full. The Series C-1 Warrants and Series C-2 Warrants each have an exercise price of $3.00 per share. The Series C-1 Warrants become exercisable beginning on the effective date of stockholder approval of the issuance of the Series C-1 Warrant Shares (the "Stockholder Approval") and will expire five years after the later of the effective date of Stockholder Approval or the effective date of a resale registration statement registering for resale all of the Series C-1 Warrant Shares. The Series C-2 Warrants are exercisable immediately upon issuance and expire 24 months after the earliest of the date that (a) the initial registration statement registering for resale all Pre-Funded Warrant Shares and Series C-2 Warrant Shares has been declared effective by the SEC, (b) all of the PIPE Warrant Shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for us to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the closing of the PIPE Transaction, provided that a holder of PIPE Warrant Shares is not an affiliate of ours, or (d) all of the PIPE Warrant Shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act, without volume or manner-of-sale restrictions (the "Effective Date"). A resale registration statement registering the resale of all of the PIPE Warrant Shares was declared effective by the SEC on July 20, 2026. Stockholder Approval was obtained at our 2026 annual meeting of stockholders (the "2026 Annual Meeting:) held on September 24, 2026. During the three months ended September 30, 2026, the holder exercised all 960,000 Pre-Funded Warrants.

H.C. Wainwright & Co., LLC ("H.C.W.") served as our exclusive placement agent in connection with the PIPE Transaction. As compensation for H.C.W. serving as our placement agent in connection with the PIPE Transaction, we paid H.C.W. a cash fee equal to 7.0% of the aggregate gross proceeds received, a management fee of 1.0% of the aggregate gross proceeds, $25,000 for non-accountable expenses and up to $50,000 for legal and other out-of-pocket expenses, and issued to designees of H.C.W. unregistered warrants (the "Placement Agent Warrants") to purchase up to an aggregate of 62,400 shares of Common Stock, equal to 6.5% of the Pre-Funded Warrant Shares sold in the PIPE Transaction. The Placement Agent Warrants have substantially the same terms as the Series C-1 Warrants, except that they are immediately exercisable for a term of five years from the Effective Date and have an exercise price of $3.9063 per share.

April 2026 Warrant Inducement

On March 31, 2026, we entered into a warrant inducement letter agreement (the "Inducement Agreement") with a holder of warrants to purchase shares of our Common Stock, which warrants were issued in a private placement offering that closed on November 4, 2024 (the "Existing Warrants"). Pursuant to the Inducement Agreement, on April 1, 2026, the holder of the Existing Warrants exercised for cash the Existing Warrants to purchase up to an aggregate of 571,430 shares of Common Stock, at the adjusted exercise price of $4.50 per share (reduced from the initial exercise price of $16.50 per share) and, in consideration for the investor's exercise of the Existing Warrants, we issued to such investor new unregistered Series B-1 Common Stock purchase warrants (the "Series B-1 Warrants") to purchase an aggregate of 571,430 shares of Common Stock and new unregistered Series B-2 Common Stock purchase warrants (the "Series B-2 Warrants" and, together with the Series B-1 Warrants, the "New Warrants") to purchase an aggregate of 571,430 shares of Common Stock. The New Warrants are immediately exercisable at an exercise price of $4.50 per share. We received aggregate gross proceeds of approximately $2.6 million from the exercise of the Existing Warrants, before deducting placement agent fees and other expenses payable by us. The Series B-1 Warrants and the Series B-2 Warrants are immediately exercisable for a term of five (5) years and eighteen (18) months, respectively, from the date that a resale registration statement registering the resale of the shares of Common Stock issuable upon exercise of the New Warrants (the "Resale Registration Statement") is declared effective by the SEC. The Resale Registration Statement was declared effective on April 29, 2026.

H.C.W. served as our exclusive placement agent in connection with the transactions consummated pursuant to the Inducement Agreement. As compensation for H.C.W. serving as our placement agent in connection with the offering, we paid H.C.W. a cash fee equal to 7.0% of the aggregate gross proceeds received upon exercise of the Existing Warrants and we issued to designees of H.C.W. warrants to purchase up to 37,143 shares of Common Stock, which warrants have substantially the same terms as the Series B-1 Warrants, except that they have an exercise price of $5.625 per share, which is equal to 125% of the exercise price of the New Warrants.

ATM Facility

During the nine months ended September 30, 2026, we sold 189,035 shares of our Common Stock through our at-the-market (ATM) facility with H.C.W. These sales were made at a weighted average price of $7.71 per share, resulting in total gross proceeds of $1,458,088 and net proceeds of $1,382,669. During the three months ended September 30, 2026, there were no sales of shares of our Common Stock through our ATM facility with H.C.W.

Other Recent Developments

On September 24, 2026, at our 2026 Annual Meeting, our stockholders approved an amendment to the 2022 Plan to increase the number of shares of the Company's Common Stock that will be available for awards under the 2022 Plan by 323,542 shares to 1,000,000 shares. As of September 30, 2026, 658,129 shares remained available for future issuance. Subsequently, on October 9, 2026, the Board approved a grant of stock options to purchase up to an aggregate of 575,000 shares of Common Stock to our officers and directors, which options have an exercise price of $0.91 per share, vested in full immediately upon grant and are exercisable for a term of ten years.

Results of Operations

Results of Operations for the Three Months Ended September 30, 2026 and 2025

The following table summarizes our results of operations for the three months ended September 30, 2026 and 2025.

Three Months Ended
September 30,
2026 2025 $ Change % Change
Operating expenses:
General and administrative expenses $ 1,040,335 $ 2,044,937 $ (1,004,602 ) (49 %)
Research and development expenses 224,576 688,465 (463,889 ) (67 %)
Depreciation expense 400 401 (1 ) (0 %)
Total operating expenses 1,265,311 2,733,803 (1,468,492 ) (54 %)
Loss from operations (1,265,311 ) (2,733,803 ) 1,468,492 (54 %)
Other income
Interest and dividend income 18,440 48,098 (29,658 ) (62 %)
Total other income 18,440 48,098 (29,658 ) (62 %)
Net loss and comprehensive loss $ (1,246,871 ) $ (2,685,705 ) $ 1,438,834 (54 %)

General and administrative expenses

General and administrative expenses were $1.0 million for the three months ended September 30, 2026, compared to $2.0 million for the three months ended September 30, 2025, a decrease of approximately $1.0 million, or 49%. The decrease was primarily attributable to a $0.7 million decrease in expenses related to being a public company and a $0.3 million decrease in stock based compensation expense.

Research and development expenses

Research and development expenses were $0.2 million for the three months ended September 30, 2026, compared to $0.7 million for the three months ended September 30, 2025, a decrease of approximately $0.5 million, or 67%. The decrease was primarily attributable to $0.2 million in expenses associated with our acquisition of frunexian pursuant to the asset purchase agreement that we entered into with eXIthera Pharmaceuticals ("eXIthera APA") completed in September 2025,which were expensed as in-process research and development ("R&D") in 2025, $0.2 million decrease in expenses associated with chemistry, manufacturing, and controls ("CMC") and a $0.1 million decrease in stock-based compensation expense. We expect research and development expenses to increase if we commence clinical trials.

Interest and dividend income

Interest and dividend income was $18,440 for the three months ended September 30, 2026, compared to $48,098 for the three months ended September 30, 2025, a decrease of $29,658, or 62%, reflecting interest and dividend income earned on our investments in money market funds.

Results of Operations for the Nine Months Ended September 30, 2026 and 2025

The following table summarizes our results of operations for the nine months ended September 30, 2026 and 2025.

Nine Months Ended September 30,
2026 2025 $ Change % Change
Operating expenses:
General and administrative expenses $ 5,417,396 $ 6,955,907 $ (1,538,511 ) (22 %)
Research and development expenses 1,701,235 3,433,845 (1,732,610 ) (50 %)
Depreciation expense 1,459 6,319 (4,860 ) (77 %)
Total operating expenses 7,120,090 10,396,071 (3,275,981 ) (32 %)
Loss from operations (7,120,090 ) (10,396,071 ) 3,275,981 (32 %)
Other income
Interest and dividend income 54,114 197,699 (143,585 ) (73 %)
Total other income 54,114 197,699 (143,585 ) (73 %)
Net loss and comprehensive loss $ (7,065,976 ) $ (10,198,372 ) $ 3,132,396 (31 %)

General and administrative expenses

General and administrative expenses for the nine months ended September 30, 2026 and 2025 were $5.4 million and $7.0 million, respectively, representing a decrease of approximately $1.5 million, or 22%. The decrease is primarily attributed to a $1.2 million decrease in expenses related to being a public company, a $0.3 million decrease in stock-based compensation. and a $0.3 million decrease in consulting expenses. These decreases were offset by a $0.3 million increase in personnel-related expenses as a result of our former Chief Financial Officer's severance agreement entered into in June 2026 and implemented annual pay raises for management in January 2026.

Research and development expenses

Research and development expenses for the nine months ended September 30, 2026 and 2025 were $1.7 million and $3.4 million, respectively, representing a decrease of $1.7 million, or 50%. The decrease is primarily attributed to a $1.3 million decrease in expenses associated with CMC, a $0.2 million decrease in expenses associated with our acquisition of frunexian pursuant to the eXIthera APA completed in September 2025 which were expense as in-process R&D, a $0.3 million decrease in stock-based compensation, a $0.3 million decrease in personnel-related expenses, and a $0.1 million decrease in clinical trial preparation costs. These decreases were offset by a $0.5 million increase in consulting expenses.

Interest and dividend income

Interest and dividend income for the nine months ended September 30, 2026 and 2025 were $0.1 million and $0.2 million, respectively. This represents the interest and dividend income earned from our investments in money market funds.

Liquidity and Capital Resources

Since inception, we have incurred recurring losses and utilized cash in operations. To date, we have funded our operations from the proceeds of the sale of convertible and promissory notes, our initial public offering completed in January 2023, our private placement offering completed in July 2023, our warrant inducements completed in November 2024 and April 2026, our private placement offering in June 2026, our registered direct offering and concurrent private placement completed in December 2025, and the sale of Common Stock through our ATM facility with H.C.W.

Our historical general and administrative (G&A) expense trajectory related to executive personnel remains unchanged by the formal appointment of Mr. Pham as Chief Business Officer, given the zero-additional-cost nature of the arrangement. Retaining Tungsten Advisors to lead our strategic review process is expected to increase professional, legal, and advisory fees in the fourth quarter of 2026 and potentially into fiscal year 2027. These costs include fixed advisory fees as well as success-based transaction metrics contingent upon completing a strategic combination or asset sale.

As of September 30, 2026, we had cash and cash equivalents of $3.1 million. For the nine months ended September 30, 2026 we reported a net loss of $7.1 million, which included $1.0 million of non-cash expenses, and cash used in operating activities of $7.2 million. We expect to continue to incur operating losses and negative cash flows for the foreseeable future if we are able to advance our clinical and regulatory activities. Based on our current operating plan, we believe that our existing cash resources will not be sufficient to fund our operating and capital requirements for the next 12 months. With our cash position of $2.7 million as of early November 2026, we believe our current capital resources are sufficient to meet immediate operating needs through the first quarter of 2027. However, our long-term liquidity profile and ability to fund any Phase 3 trial remain heavily dependent on securing non-dilutive capital, strategic licensing fees, or equity financing arising from the ongoing strategic evaluation process. To date, we have not been successful in raising sufficient funds to allow us to complete any clinical trials, and we will not commence a trial that we do not believe we have sufficient funding to complete. No assurances can be provided and our cash runway could differ materially from our expectations based on various factors, many of which are out of our control. To meet our capital needs, management is focusing on securing additional funds, which may include strategic partnerships, out-licensing agreements, or alternative non-dilutive funding or sales under our ATM facility with H.C.W., equity offerings, debt financings, or a combination thereof. However, there can be no assurance that we will be able to complete partnering transactions or financings on terms acceptable to us or at all or that we will be awarded any grant funding. These factors raise substantial doubt about our ability to continue as a going concern for at least one year following the issuance of the accompanying financial statements. If we are unable to monetize our assets or obtain additional funding, we may be required to delay, scale back or discontinue development programs, liquidate intellectual property or other assets, or cease operations entirely. The accompanying financial statements do not include any adjustments that might result from this uncertainty.

Because of the uncertainty our ability to raise sufficient capital, on October 7, 2026, we announced that our Board of Directors initiated a formal strategic process to evaluate opportunities to maximize the value of the Company and our assets. Potential opportunities may include licensing or sale of individual assets, development and commercialization partnerships, portfolio transactions, business combinations, reverse merger or other strategic transactions.

Cash Flows

The following table summarizes our cash flows for the period presented:

Nine Months Ended
September 30,
2026 2025
Cash used in operating activities $ (7,150,976 ) $ (10,031,707 )
Cash used in investing activities - (5,104 )
Cash provided by financing activities 6,199,273 3,878,951
Net change in cash (951,703 ) (6,157,860 )
Cash and cash equivalents, beginning of period 4,007,789 10,017,942
Cash and cash equivalents, end of period $ 3,056,086 $ 3,860,082

Operating activities

During the nine months ended September 30, 2026, cash used in operating activities was $7.2 million. Net loss adjusted for the non-cash items as detailed on the statement of cash flows, used $6.0 million in cash, and the changes in operating assets and liabilities, as detailed on the statement of cash flows, used $1.1 million in cash primarily from a $0.9 million decrease in accrued liabilities, a $0.2 million decrease in accounts payable, and a $0.1 million increase in prepaid expenses.

During the nine months ended September 30, 2025, cash used in operating activities was $10.0 million. Net loss adjusted for the non-cash items as detailed on the statement of cash flows, used $8.6 million in cash, and the changes in operating assets and liabilities, as detailed on the statement of cash flows, used $1.5 million in cash primarily from a $0.9 million decrease in accounts payable, a $0.4 million decrease in accrued liabilities, and a $0.1 million increase in prepaid expenses.

Financing activities

During the nine months ended September 30, 2026, net cash provided by financing activities totaled $6.2 million primarily consisting of $2.6 million net proceeds from warrant issuances, $2.2 million net proceeds received from the April 2026 warrant inducement and $1.4 million received upon the sales of Common Stock in our ATM facility.

During the nine months ended September 30, 2025, net cash provided by financing activities totaled $3.9 million from the sale of Common Stock in our ATM facility and proceeds from the exercise of stock options.

Critical Accounting Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. Significant estimates and assumptions made in the accompanying financial statements include but are not limited to the fair value of financial instruments, the fair value of stock-based awards, deferred tax assets and valuation allowance, income tax uncertainties, and certain accruals. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimated under different assumptions or conditions.

Stock-Based Compensation

We measure our stock-based awards granted to employees, consultants and directors based on the estimated grant-date fair values of the awards and recognize the compensation over the requisite service period. We use the Black-Scholes option-pricing model to estimate the fair value of our stock option awards. Stock-based compensation is recognized using the straight-line method. As the stock compensation expense is based on awards ultimately expected to vest, it is reduced by forfeitures. We account for forfeitures as they occur.

OFF-BALANCE SHEET ARRANGEMENTS

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

Cadrenal Therapeutics Inc. published this content on November 16, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on November 16, 2026 at 22:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]